Shares of Eleven Biotherapeutics Inc (NASDAQ: EBIO) popped 68.54% to $1.50 after the company announced their strategic update and quarterly financial results. Stock prices advanced $0.61 per share while volume surged to 14.56 million shares compared to the average daily volume of 842,081 shares. With those gains, Eleven Biotherapeutics Inc...
Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) could pick up some upside this week if the agency approves its lead schizophrenia candidate. Here's why. The coming week is set to be a big one in the development stage biotech space, with a number of companies scheduled to report what could be game changing data. The FDA...
Premarket on Wednesday, April 20, 2016, development stage biotech company MediciNova, Inc. (NASDAQ:MNOV) reported interim data from its ongoing trial of MN-166 – its lead amyotrophic lateral sclerosis (ALS) candidate. The company lost strength on Tuesday, but could well pick up a market capitalization boost across Wednesday’s session in...
At the beginning of April, 2016, Minnesota based biotech Vascular Solutions, Inc. (NASDAQ:VASC) reported that it was withdrawing and recalling a large number of its lead product, its Guardian® II Hemostasis Valves, from the market. The recall came on the back of findings that suggested the product could leak,...
Aeglea Bio Therapeutics Inc (NASDAQ:AGLE), a Texas based development stage biotech company, just gave us an update regarding its intentions to report (present) data at an upcoming conference. The data, which relates to its early stage oncology candidate AEB1102, will hit press as part of a scientific poster session at...